Heart Failure Clinical Research

You may be eligible if you:

• Are 30-85 years old (inclusive)
• Have heart failure
• Have a reduced ejection fraction (≤35%)

There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study-related medication and study-related medical exams at no cost and a stipend for time and travel. No health insurance is required to participate. 

For more information call

(352) 341-2100

Or sign up below, and our friendly staff will call you!

Heart Failure Research

With heart failure, the heart becomes incapable of pumping enough blood to meet the needs of the entire body. This condition affects millions of Americans and can limit how much ordinary physical activity people can perform. Despite long-term trends, recent data shows that the rate of heart failure is on the rise for many Americans. Clinical research is needed to address this growing concern. 

Jacksonville Center for Clinical Research is conducting a research study for volunteers to evaluate an investigational medication for people with Heart Failure and a reduced ejection fraction. 

 You may be eligible to participate if you: 

• Are 18+ years old 

• Have symptoms of heart failure 

• • Shortness of breath 

• • Fatigue 

• • Chest pain 

• Have an Ejection Fraction (LVEF) less than 50% 

• Have been on stable ACE inhibitor, ARB medication, or Entresto for at least 1 month 

There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study-related medication and medical exams at no cost, along with a stipend for time and travel. No health insurance is required to participate. 

For more information call 

(904) 730-0166

Or sign up below, and our friendly staff will call you!

BOIN 1378-0018 HFrEF (MJK)

Purpose of the Study:

This study is testing whether vicadrostat plus empagliflozin can help people with chronic heart failure whose heart pumping function is reduced (LVEF less than 40%). Participants must have been diagnosed with heart failure for at least 3 months.

You may be able to join this study if you:

• Are 18 years of age or older
• Have had heart failure for at least 3 months
• Have a weakened heart pumping function (LVEF less than 40%)
• Have ongoing heart failure symptoms
• Are receiving standard treatment for heart failure

You may not be able to join this study if you:

• Take certain medications that are not allowed during the study
• Recently had a serious heart-related event, such as a heart attack or stroke
• Recently had major surgery or a major heart procedure
• Have severe worsening of heart failure requiring intensive treatment
• Have had a heart transplant, are waiting for one, or use a heart assist device
• Have certain uncommon heart diseases or recent inflammation of the heart

Additional eligibility criteria apply.

Why participate?

• Help advance research in heart disease prevention
•  Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

NOVO NN9490-8266 HFpEF HFmrEF (ELS) POLARIS

Purpose of the Study:

This study is testing a new medication called NNC0487-0111 to see if it can safely help people with certain types of heart failure (HFpEF or HFmrEF) who also have excess body weight.

You may qualify if you:

• Have HFpEF or HFmrEF (a type of heart failure).
• Have a BMI of 30 or higher.
• Have stable heart failure symptoms.
• If you have type 2 diabetes, you were diagnosed at least 30 days ago.

You may not qualify if you:

• Had a recent heart attack, stroke, or worsening heart failure.
• Have certain serious heart or lung conditions.
• Have type 1 diabetes.
• Have significant diabetes-related eye disease.
• Have poorly controlled diabetes (HbA1c greater than 10%).

A study team member will review your medical history to determine if the study is right for you.

Why participate?

• Help advance research in heart disease prevention
•  Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

Below is the study criteria information publicly available from Clinicaltrials.gov

• • • 18 Years to 70 Years (Adult, Older Adult)
    • Diagnosis of HeFH or premature CAD

• • • Homozygous familial hypercholesterolemia
    • Active or history of chronic liver disease
    • Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
    • Clinically significant or abnormal laboratory values as defined by the protocol

About this Study:

This study is evaluating an investigational treatment aimed at lowering the risk of heart disease in individuals with high Lipoprotein(a) [Lp(a)] and other risk factors. You may be eligible if you have elevated levels of this genetic cholesterol marker.

You may qualify if you:

• Are 50 years of age or older

• Have high Lp(a) levels (≥200 nmol/L)
• Have risk factors for heart disease such as:

• High blood pressure

• • Diabetes
  • High cholesterol
  • Smoking history
• Or have evidence of plaque buildup in your arteries

 You may not qualify if you have:

• A prior heart attack, stroke, or TIA

• Had stents, bypass surgery, or plan to have one soon
• A history of major bleeding disorders

Why participate?

• Help advance research in heart disease prevention

• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

About this Study:

The study  is designed to test whether a specific drug targeting Lp can reduce the risk of first major cardiovascular (CV) events.

You may qualify if you:

• Age ≥50 years
• Elevated (Lipoprotein (a)) Lp(a) during screening
• Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis

 You may not qualify if you have:

• Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
• Prior or planned arterial revascularization
• History of major bleeding disorder

Why participate?

• Help advance research in heart disease prevention

• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

You may qualify if:

• You are 40 years or older

• You have high lipoprotein(a) [Lp(a)]  -done at screening visit
• You have a higher risk of heart disease, such as:

• Coronary artery disease (CAD)

• • Prior stroke
  • Peripheral artery disease
  • Or conditions like familial high cholesterol or type 2 diabetes
• You have been on a stable dose of certain medications for at least 4 weeks, including:

• Cholesterol-lowering medications

• • Hormone-related treatments (such as estrogen, testosterone, etc.)
• Your body mass index (BMI) is between 18.5 and 40

Why participate?

• Help advance research in heart disease prevention

• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

You may qualify if you:

• Are 18 to 80 years old

• Have been diagnosed with atherosclerotic cardiovascular disease (heart or blood vessel disease caused by plaque buildup)
• Have elevated lipoprotein(a), or Lp(a) — a type of cholesterol in your blood
• Meet other study requirements (the research team will review these with you)

 You may not qualify if you have:

• Have moderate to severe heart failure or your heart is very weak (ejection fraction below 30%)
• Have very high, uncontrolled blood pressure (160+/100+)
• Had serious or uncontrolled heart rhythm problems in the last 3 months
• Had cancer in the past 5 years, except for certain early-stage or treated cancers
• Do not meet other study requirements (the team will review this with you)

Why participate?

• Help advance research in heart disease prevention

• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

• You may qualify if you:
• Are 18–80 years old

• Have heart/vascular disease (heart attack, stroke, blocked arteries) 
• Have high Lp(a) and LDL >70 mg/dL
• Are on stable cholesterol treatment
• Meet other study requirements (the research team will review these with you)

You may NOT qualify if you:

• Had a recent heart attack, stroke, or surgery

• Have severe heart failure or uncontrolled BP 
• Have serious liver or kidney disease

Recently used certain advanced cholesterol drugs 

• Do not meet other study requirements (the team will review this with you)

Why participate?

• Help advance research in heart disease prevention

• Compensation may be available (if applicable)

Study Details: 

Location: Jacksonville, FL 

All study- related care is provided at no cost to you or your insurance company.

ELIL J3L-MC-EZEJ Lp(a) CCTA (ELS)

About this study:

This study is for people who have high levels of lipoprotein(a), also called Lp(a), a type of cholesterol in the blood that can increase the risk of heart disease. Researchers are studying whether a medication called lepodisiran can lower Lp(a) and help reduce harmful buildup (plaque) in the heart’s blood vessels.

You may qualify if:

• Your Lp(a) is high (≥175)

• You have heart disease or are at high risk for it
• A heart scan (CCTA) shows plaque in your arteries
• Your cholesterol medications have been stable for at least 8 weeks

You may NOT qualify if:

• You had a recent heart attack or stroke (within 60 days)

• You have serious kidney or heart failure
• You’ve had bypass surgery (CABG)
• You’re planning a heart procedure soon (stent, surgery, etc.)
• You’ve received special treatments to lower Lp(a)
• You can’t safely undergo a CT scan (contrast allergy, etc.)

Why participate?

• Help advance research in heart disease prevention
• Compensation may be available (if applicable) )

Study Details: 

Location: Jacksonville, FL 

All study-related care is provided at no cost to you or your insurance company.